demonstrated that EBV+DLBCL had a higher percentage of CD30 expression than EBV-DLBCL and that CD30+EBV+DLBCL had a lower survival rate than CD30+EBV-DLBCL patients (8). This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.